Eltrombopag, marketed as Revolade, belongs to the thrombopoietin receptor agonist class of orally administered medicines used to raise platelet counts in adults and children with chronic immune thrombocytopenia. The presentation referenced here is a 25 mg tablet supplied 14 tablets per bottle, a format commonly seen in clinical and distribution channels. Rather than suppressing platelet destruction, eltrombopag works by stimulating new platelet production, which makes it a logical component of combination or sequenced approaches.
In chronic immune thrombocytopenia, eltrombopag is frequently positioned alongside other lines of therapy rather than as an isolated intervention. Clinicians may use it with corticosteroids, danazol, or azathioprine, or as a bridge when prior options have not delivered durable responses. Because its mechanism - binding and activating thrombopoietin receptors on bone marrow cells - is additive to therapies that reduce immune-mediated platelet breakdown, the two strategies address different parts of the disease physiology.
For procurement and formulary teams, this combination context matters: demand for eltrombopag often tracks with centers running structured ITP protocols, so reorder patterns should reflect ongoing rather than one-off use. The 25 mg strength is the typical starting reference point, with dose adjustment guided by serial platelet monitoring.
Eltrombopag also has a recognized role in thrombocytopenia associated with chronic hepatitis C, where raising the platelet count can enable patients to begin or complete interferon-based antiviral regimens that would otherwise be unsafe. In this setting the agent is used temporarily around the antiviral course rather than indefinitely. A separate approved use is in adults with severe aplastic anemia who are not controlled on immunosuppressive therapy.
These varied indications mean that buyers servicing multi-specialty hospitals should anticipate demand from both hematology and hepatology departments. Matching the exact registered strength and pack - 25 mg tablets in a 14-count bottle - to the intended protocol reduces substitution errors and supports clean inventory rotation.
Q: Does eltrombopag stop platelets from being destroyed? A: No. Unlike some ITP therapies that reduce immune destruction, eltrombopag stimulates the bone marrow to produce more platelets by activating thrombopoietin receptors.
Q: Why is eltrombopag used with other ITP medicines? A: Its production-stimulating action complements therapies that limit platelet breakdown, allowing clinicians to target both sides of the low-platelet problem.
Q: Is the 25 mg x 14 bottle the only format available? A: No, eltrombopag is available in multiple strengths; the 25 mg, 14-tablet bottle is one common presentation used in both ITP and hepatitis C-related thrombocytopenia.
Q: How does eltrombopag help hepatitis C patients specifically? A: By raising platelet counts, it can allow patients with HCV-associated thrombocytopenia to start or finish antiviral therapy that requires a minimum platelet threshold.
Eltrombopag, marketed as Revolade, belongs to the thrombopoietin receptor agonist class of orally administered medicines used to raise platelet counts in adults and children with chronic immune thrombocytopenia. The presentation referenced here is a 25 mg tablet supplied 14 tablets per bottle, a format commonly seen in clinical and distribution channels. Rather than suppressing platelet destruction, eltrombopag works by stimulating new platelet production, which makes it a logical component of combination or sequenced approaches.
In chronic immune thrombocytopenia, eltrombopag is frequently positioned alongside other lines of therapy rather than as an isolated intervention. Clinicians may use it with corticosteroids, danazol, or azathioprine, or as a bridge when prior options have not delivered durable responses. Because its mechanism - binding and activating thrombopoietin receptors on bone marrow cells - is additive to therapies that reduce immune-mediated platelet breakdown, the two strategies address different parts of the disease physiology.
For procurement and formulary teams, this combination context matters: demand for eltrombopag often tracks with centers running structured ITP protocols, so reorder patterns should reflect ongoing rather than one-off use. The 25 mg strength is the typical starting reference point, with dose adjustment guided by serial platelet monitoring.
Eltrombopag also has a recognized role in thrombocytopenia associated with chronic hepatitis C, where raising the platelet count can enable patients to begin or complete interferon-based antiviral regimens that would otherwise be unsafe. In this setting the agent is used temporarily around the antiviral course rather than indefinitely. A separate approved use is in adults with severe aplastic anemia who are not controlled on immunosuppressive therapy.
These varied indications mean that buyers servicing multi-specialty hospitals should anticipate demand from both hematology and hepatology departments. Matching the exact registered strength and pack - 25 mg tablets in a 14-count bottle - to the intended protocol reduces substitution errors and supports clean inventory rotation.
Q: Does eltrombopag stop platelets from being destroyed? A: No. Unlike some ITP therapies that reduce immune destruction, eltrombopag stimulates the bone marrow to produce more platelets by activating thrombopoietin receptors.
Q: Why is eltrombopag used with other ITP medicines? A: Its production-stimulating action complements therapies that limit platelet breakdown, allowing clinicians to target both sides of the low-platelet problem.
Q: Is the 25 mg x 14 bottle the only format available? A: No, eltrombopag is available in multiple strengths; the 25 mg, 14-tablet bottle is one common presentation used in both ITP and hepatitis C-related thrombocytopenia.
Q: How does eltrombopag help hepatitis C patients specifically? A: By raising platelet counts, it can allow patients with HCV-associated thrombocytopenia to start or finish antiviral therapy that requires a minimum platelet threshold.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
